MD Medical Group Posts Strong Growth Across All Operational Indicators for 9m 2016
en
24.10.2016

MD Medical Group Investments Plc (“MD Medical Group”, “MDMG” or the “Company” – LSE: MDMG), a leading Russian private healthcare provider, today announces its operating results for the third quarter and nine months of 2016.

Key operational highlights for 9M 2016:

  • Total deliveries increased 22% year-on-year (y-o-y) to 5,018
  • Total IVF cycles increased 52% y-o-y to 10,011
  • Total in-patient treatments increased 11% y-o-y to 41,582
  • Total out-patient treatments increased 18% y-o-y to 1,018,117

Mark Kurtser, CEO of MD Medical Group, said:

“Nine months is an important period, especially in our business. And we are glad to announce that thanks to continued strong growth across all operational parameters in Q3 we have successfully completed the first nine months of 2016.
“During the period we had 22% more deliveries than in 9M 2015. The number of IVF cycles grew by more than 1.5x and has already exceeded the results of FY 2015. No other company in Russia ever completed more than 10,000 IVF cycles within a nine-month period. In-patient and out-patient treatments grew 11% and 18% year-on-year, respectively.
“Key drivers of this growth included continued ramp-up at our Lapino, Ufa and PMC hospitals. The remarkable growth in the IVF segment was largely driven by our new clinics in Siberia, which delivered approximately 2,000 cycles, as well as other clinics.
“We are satisfied with our dynamics this year to date and are committed to maintaining the positive trend going forward in 2016.”

Deliveries

  • In 9M 2016, total deliveries increased 22% y-o-y to 5,018.
  • In Q3 2016, total deliveries increased 24% y-o-y to 1,815.
  • In 9M 2016, there were 786 deliveries at Mother & Child Ufa hospital.

IVF

  • In 9M 2016, total IVF cycles rose 52% y-o-y to 10,011.
  • In Q3 2016, total IVF cycles rose 44% y-o-y to 3,443.
  • In 9M 2016, LFL[1] 8,069 IVF cycles were performed, up 22% y-o-y.

In-patient treatments

  • In 9M 2016, total in-patient treatments grew 11% y-o-y to 41,582, driven by:
    • 4% increase in OBGYN in-patient treatments;
    • 21% increase in paediatric in-patient treatments;
    • 12% increase in in-patient days using other medical services.
  • In Q3 2016, the total number of in-patient days increased 16% y-o-y to 13,432.
  • In 9M 2016, LFL in-patient treatments increased 11% y-o-y to 41,540.

Out-patient treatments

  • In 9M 2016, the total number of out-patient treatments increased 18% y-o-y to 1,018,117, driven by:
    • 12% increase in OBGYN out-patient treatments;
    • 15% rise in paediatric out-patient visits;
    • 28% increase in other medical services.
  • In Q3 2016, the total number of out-patient treatments increased 16% y-o-y to 338,499.
  • In 9M 2016, LFL out-patient treatments increased 11% y-o-y to 954,642.

[1] LFL data does not include figures for the Medica clinic (Novokuznetsk) and ARTMedGroup clinics (Krasnoyarsk, Omsk, Barnaul, and Novosibirsk), which have been consolidated since January 2016, as well as figures for the Kostroma clinic, which opened in April 2016.

Total

LFL

 
9M 16
9M 15
y-o-y,
%
3Q 2016
3Q 2015
y-o-y,
%
9M 2016
9M 2015
y-o-y,
%
Obstetrics and Gynaecology
Deliveries
5,018
4,113
      22%
           1,815
           1,462
        21%
            5,018
           4,113
       22%
In-patient treatments (except deliveries)
18,027

17,397

4%
6,057
5,687
2%
18,027
17,397
4%
Out-patient treatments
374,619
334,204
12%
127,690
 113,907
12%
   358,428
   334,204
7%
IVF

 

10,011

6,603

52%

3,443

2,392

56%

8,069

6,603

22%

 

Paediatrics
In-patient treatments

13,706

11,373
21%
4,313
3,114
14%
13,706
11,373
21%
Out-patient treatments
287,841
251,030
15%
95,181
82,887
15%
287,663
251,030
15%
Other medical services
In-patient treatments
9,49
8,780
12%
3,062
2,800
13%
9,807
8,780
12%
Out-patient treatments
355,657
277,591
28%
115,628
90,261
27%
308,551
277,591
11%

Total

 

Total deliveries
5,018
4,113
22%
1,815
1,462
21%
5,018
4,113
22%
Total IVF
10,011
6,603
52%
3,443
2,392
56%
8,069
6,603
22%
Total in-patient treatments
41,582
37,550
11%
13,442
11,601
8%
41,540
37,550
11%
Total out-patient treatments
  1,018,117
  862,825
18%
338,499
287,055
18%
954,642
862,825
11%

For further information please contact:

Investors

Media

Elena Romanova

MD Medical Group Investments Plc

Tel: +7 495 331 4120
e.romanova@mcclinics.ru

EM

Tom Blackwell: +7 919 102 9064

Sergii Pershyn: +1 929 855 8188

MDMG@em-comms.com


About MD Medical Group

MD Medical Group operates in the highly attractive Russian private healthcare service market and has a leading position in high-quality women's health and paediatrics. The company manages 31 modern healthcare facilities, including 4 hospitals and 27 outpatient clinics in Moscow and Moscow region, St. Petersburg, Ufa, Perm, Samara and Samara region, Irkutsk, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, and Barnaul.

The Company’s shares have been listed on the London Stock Exchange (LSE ticker “MDMG”) in the form of Global Depositary Receipts (GDRs) since 12 October 2012.

Forward-Looking Statements:

This press release contains forward looking statements, which are based on the Company’s current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company’s ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.

No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.


Back to news list